

## STUDY DEMONSTRATES EFFICACY AND COST SAVINGS OF MYRIAD™ IN LOWER LIMB RECONSTRUCTION PROCEDURES

### Highlights

- Largest prospective inpatient study of its kind to date
- Patients were at high risk of amputation and complications
- Myriad achieved successful tissue coverage and tissue fill with a median of just one application
- Myriad achieved 100% tissue coverage and fill in 30 days with no infections or complications
- Study findings show potential cost savings of up to 195% compared with other commercially available dermal substitutes

Aroa Biosurgery Limited (ASX: ARX, 'AROA' or the 'Company') is pleased to announce that the first publication from the ongoing prospective study "Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR)" has been published in the December issue of highly respected journal, *Plastic and Reconstructive Surgery – Global Open*.

The peer-reviewed real-world study, titled *Limb Salvage via Surgical Soft Tissue Reconstruction with Ovine Forestomach Matrix Graft: A prospective study*, is the largest prospective inpatient study of lower extremity reconstructions using a dermal substitute.

The single site study conducted during the period May 2022 to April 2023, included a total of 130 lower limb defects from 120 patients. Across all participants, 95% had at least one risk factor for lower limb amputation, and 55% had three or more predictive risk factors for amputation.

Lower limb amputation can severely impact quality of life, and the 5-year mortality rate for patients receiving a lower limb amputation can be up to ~50%<sup>1</sup>.

The study found that AROA's Myriad Matrix™ and Myriad Morcells™ achieved successful tissue coverage and fill in 30 days with just one application and no infections or complications, reinforcing its efficacy in lower limb reconstruction procedures.

The study further showed estimated cost savings of up to 195% compared to other commercially available dermal matrices when used for lower extremity reconstruction.

The findings from this recent prospective study further validate use of Myriad products in these challenging lower extremity reconstructions<sup>2</sup>.

AROA Founder and CEO Brian Ward says: "We are very pleased to see the first clinical evidence emerge from our large prospective MASTRR study. The evidence from this study further validates both the efficacy of, and potential cost benefits associated with Myriad use in lower limb reconstruction procedures. With a total addressable market of \$225 million USD<sup>3</sup>, for lower limb procedures alone, this represents a considerable opportunity for AROA."

<sup>1</sup> Armstrong, D.G., et al, *Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer*. Journal of Foot and Ankle Research, 2020. 13(1): p. 16.

<sup>2</sup> Bosque, B.A., et al, *Ovine Forestomach Matrix in the Surgical Management of Complex Lower-Extremity Soft-Tissue Defects*. Journal of American Podiatric Medical Association, 2023. 113(3).

<sup>3</sup> AROA Management estimates

The study is available online, [here](#).

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

### **Contacts**

**Investor Relations**  
[investor@aroa.com](mailto:investor@aroa.com)

**Media**  
[sarah.tora@aroa.com](mailto:sarah.tora@aroa.com)

### **About AROA™**

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach.

Over 6 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). [www.aroa.com](http://www.aroa.com)

### **About Myriad™**

Myriad Matrix™ is an extracellular matrix graft, composed of AROA ECM and designed for soft tissue reconstruction and complex wounds. Myriad Morcells™ is a morcellised version of Myriad Matrix that easily conforms to optimize contact with irregular wound beds. Myriad Morcells Fine is a morselized conformable ECM graft that can be used either by itself or synergistically with Myriad Matrix.

### **About Endoform™**

Endoform™ products are unique extracellular matrix products, composed of AROA ECM, for the management of acute and chronic wounds.

### **About Symphony™**

Symphony is a new product which has been developed off the strength of AROA ECM. It is applied as a graft and is surgically fixed at the margins. It is designed to support healing during the proliferative phase to reduce time to wound closure, particularly in patients whose healing is severely impaired or compromised due to disease.

### **About Enivo™**

This is a new tissue apposition system which AROA is developing, designed to close tissue cavities at a surgical site created by surgical dissection or tissue removal. It is comprised of a specially designed AROA ECM implant that is coupled to an external single-use negative pressure pump.

When the product is deployed, the tissue surfaces are drawn together, held in place and tissue fluids are carried by the vacuum to an external fluid collection bag. AROA intends to develop and launch a new class of products utilising this new platform technology.